IL Biotechnology & Medical Research

Chemomab Therapeutics Ltd (CMMB)

Track

Track

Chemomab Therapeutics witnessed two sell transactions by Neil Harris Cohen totaling $6,516.40 over the past ninety days. These divestments occurred amidst a 28.4% decline in stock value. No executive buying activity was recorded recently, following the company's latest September results financiers report.
Ticker: CMMB Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Chemomab Therapeutics Ltd. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.8
Cohen Neil Harris Non-Executive Director
Transaction date
Sale
Price
105.40
Quantity 60,342 -18.9%
Value US$1,024,499
1.8
Cohen Neil Harris Non-Executive Director
Transaction date
Sale
Price
173.07
Quantity 71,989 -6.9%
Value US$3,301,394
2.8
Mor George Adi Chief Scientific Officer Executive Director
Transaction date
Planned sale
Price
5.03
Quantity 6,100 -2.4%
Value US$30,663
2.8
Mor George Adi Chief Scientific Officer Executive Director
Transaction date
Planned sale
Price
5.03
Quantity 7,700 -2.4%
Value US$38,706
3.9
OrbiMed Israel GP Ltd. Large shareholder
Transaction date
Sale
Price
4.51
Quantity 70,524 -3.1%
Value US$318,063
3.9
OrbiMed Israel GP Ltd. Large shareholder
Transaction date
Sale
Price
3.34
Quantity 266,376 -10.3%
Value US$889,696
1.8
Cohen Neil Harris Non-Executive Director
Transaction date
Sale
Price
2.00
Quantity 2,409 -19.4%
Value US$4,818
2.8
Mor George Adi Chief Scientific Officer Executive Director
Transaction date
Sale
Price
2.08
Quantity 257,248 -50.0%
Value US$536,311
2.8
Mor George Adi Chief Scientific Officer Executive Director
Transaction date
Sale
Price
2.08
Quantity 324,775 -50.0%
Value US$677,091
1.4
Maryles Joel Michael Non-Executive Director
Transaction date
Purchase
Price
2.76
Quantity 33 +2.4%
Value US$91
1.4
Maryles Joel Michael Non-Executive Director
Transaction date
Purchase
Price
2.89
Quantity 400 +40.0%
Value US$1,156
1.8
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
3.19
Quantity 2,000 +19.2%
Value US$6,380
1.4
Maryles Joel Michael Non-Executive Director
Transaction date
Purchase
Price
4.36
Quantity 500 +100.0%
Value US$2,180
1.4
Maryles Joel Michael Non-Executive Director
Transaction date
Purchase
Price
4.32
Quantity 500 +inf%
Value US$2,160
3.2
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
3.25
Quantity 250 +14.3%
Value US$812
3.2
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
3.30
Quantity 250 +16.7%
Value US$825
3.2
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
4.20
Quantity 250 +20.0%
Value US$1,050
3.2
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
4.10
Quantity 250 +25.0%
Value US$1,025
3.2
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
3.90
Quantity 250 +33.3%
Value US$975
3.2
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
3.98
Quantity 250 +100.0%
Value US$995
3.2
Marvin Donald Executive VP, CFO & COO Officer
Transaction date
Purchase
Price
4.00
Quantity 250 +inf%
Value US$1,000
1.4
Pfost Dale R Chief Executive Officer Executive Director
Transaction date
Purchase
Price
3.97
Quantity 700 +38.9%
Value US$2,779
1.4
Pfost Dale R Chief Executive Officer Executive Director
Transaction date
Purchase
Price
3.98
Quantity 1,800 +inf%
Value US$7,164
1.8
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
4.56
Quantity 2,000 +23.8%
Value US$9,120
1.8
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
4.30
Quantity 2,000 +31.2%
Value US$8,600
1.8
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
4.20
Quantity 2,000 +45.4%
Value US$8,400
0.9
Darvish Nissim Non-Executive Director
Transaction date
Purchase
Price
4.28
Quantity 1,200 +inf%
Value US$5,136
1.8
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
7.43
Quantity 2,000 +83.0%
Value US$14,860
1.8
Cohen Neil Harris Non-Executive Director
Transaction date
Purchase
Price
41.51
Quantity 2,409 +inf%
Value US$99,998
1.3
THIEL PETER Large shareholder
Transaction date
Purchase
Price
0.00
Quantity 230,536
Value US$0
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-01 2026-08-28 S Sale
1.8
Cohen Neil Harris
Non-Executive Director
60,342 -18.9%
105.40
US$1,024,499 		60,342 -18.9% 105.40 US$1,024,499
2026-09-01 2026-08-27 S Sale
1.8
Cohen Neil Harris
Non-Executive Director
71,989 -6.9%
173.07
US$3,301,394 		71,989 -6.9% 173.07 US$3,301,394
2024-09-12 2024-09-12 PrS Proposed sale
3.9
OrbiMed Israel Partners Limited Partnership

Owner
88,377
185.83
US$796,561 		88,377 185.83 US$796,561
2023-01-05 2023-01-03 PlS Planned sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
6,100 -2.4%
5.03
US$30,663 		6,100 -2.4% 5.03 US$30,663
2023-01-05 2023-01-03 PlS Planned sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
7,700 -2.4%
5.03
US$38,706 		7,700 -2.4% 5.03 US$38,706
2023-01-05 2023-01-03 S Sale
3.9
OrbiMed Israel GP Ltd.
Large shareholder
70,524 -3.1%
4.51
US$318,063 		70,524 -3.1% 4.51 US$318,063
2023-01-05 2023-01-03 S Sale
3.9
OrbiMed Israel GP Ltd.
Large shareholder
266,376 -10.3%
3.34
US$889,696 		266,376 -10.3% 3.34 US$889,696
2022-11-18 2022-11-16 S Sale
1.8
Cohen Neil Harris
Non-Executive Director
2,409 -19.4%
2.00
US$4,818 		2,409 -19.4% 2.00 US$4,818
2022-11-17 2022-11-16 S Sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
257,248 -50.0%
2.08
US$536,311 		257,248 -50.0% 2.08 US$536,311
2022-11-17 2022-11-16 S Sale
2.8
Mor George Adi

Chief Scientific Officer

Executive Director
324,775 -50.0%
2.08
US$677,091 		324,775 -50.0% 2.08 US$677,091
2022-05-25 2022-05-24 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
33 +2.4%
2.76
US$91 		33 +2.4% 2.76 US$91
2022-05-25 2022-05-24 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
400 +40.0%
2.89
US$1,156 		400 +40.0% 2.89 US$1,156
2022-05-19 2022-05-18 B Purchase
1.8
Cohen Neil Harris
Non-Executive Director
2,000 +19.2%
3.19
US$6,380 		2,000 +19.2% 3.19 US$6,380
2022-03-21 2022-03-18 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
500 +100.0%
4.36
US$2,180 		500 +100.0% 4.36 US$2,180
2022-03-21 2022-03-18 B Purchase
1.4
Maryles Joel Michael
Non-Executive Director
500 +inf%
4.32
US$2,160 		500 +inf% 4.32 US$2,160
2022-06-21 2022-03-16 B Purchase
3.2
Marvin Donald

Executive VP, CFO & COO

Officer
250 +14.3%
3.25
US$812 		250 +14.3% 3.25 US$812
2022-06-21 2022-03-16 B Purchase
3.2
Marvin Donald

Executive VP, CFO & COO

Officer
250 +16.7%
3.30
US$825 		250 +16.7% 3.30 US$825
2022-03-21 2022-03-14 B Purchase
3.2
Marvin Donald

Executive VP, CFO & COO

Officer
250 +20.0%
4.20
US$1,050 		250 +20.0% 4.20 US$1,050
2022-03-21 2022-03-14 B Purchase
3.2
Marvin Donald

Executive VP, CFO & COO

Officer
250 +25.0%
4.10
US$1,025 		250 +25.0% 4.10 US$1,025
2022-03-21 2022-03-14 B Purchase
3.2
Marvin Donald

Executive VP, CFO & COO

Officer
250 +33.3%
3.90
US$975 		250 +33.3% 3.90 US$975
2022-03-21 2022-03-14 B Purchase
3.2
Marvin Donald

Executive VP, CFO & COO

Officer
250 +100.0%
3.98
US$995 		250 +100.0% 3.98 US$995
2022-03-21 2022-03-14 B Purchase
3.2
Marvin Donald

Executive VP, CFO & COO

Officer
250 +inf%
4.00
US$1,000 		250 +inf% 4.00 US$1,000
2022-03-15 2022-03-14 B Purchase
1.4
Pfost Dale R

Chief Executive Officer

Executive Director
700 +38.9%
3.97
US$2,779 		700 +38.9% 3.97 US$2,779
2022-03-15 2022-03-14 B Purchase
1.4
Pfost Dale R

Chief Executive Officer

Executive Director
1,800 +inf%
3.98
US$7,164 		1,800 +inf% 3.98 US$7,164
2022-03-15 2022-03-14 B Purchase
1.8
Cohen Neil Harris
Non-Executive Director
2,000 +23.8%
4.56
US$9,120 		2,000 +23.8% 4.56 US$9,120
2022-03-15 2022-03-14 B Purchase
1.8
Cohen Neil Harris
Non-Executive Director
2,000 +31.2%
4.30
US$8,600 		2,000 +31.2% 4.30 US$8,600
2022-03-15 2022-03-14 B Purchase
1.8
Cohen Neil Harris
Non-Executive Director
2,000 +45.4%
4.20
US$8,400 		2,000 +45.4% 4.20 US$8,400
2022-03-14 2022-03-11 B Purchase
0.9
Darvish Nissim
Non-Executive Director
1,200 +inf%
4.28
US$5,136 		1,200 +inf% 4.28 US$5,136
2021-12-08 2021-12-06 B Purchase
1.8
Cohen Neil Harris
Non-Executive Director
2,000 +83.0%
7.43
US$14,860 		2,000 +83.0% 7.43 US$14,860
2021-03-26 2021-03-16 B Purchase
1.8
Cohen Neil Harris
Non-Executive Director
2,409 +inf%
41.51
US$99,998 		2,409 +inf% 41.51 US$99,998
2021-03-18 2021-03-16 B Purchase
1.3
THIEL PETER
Large shareholder
230,536
0.00
US$0 		230,536 0.00 US$0
Explore more

More insider trading research around Chemomab Therapeutics Ltd

More insider trades in IL
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity